[HTML][HTML] The biological roles and clinical applications of the PI3K/AKT pathway in targeted therapy resistance in HER2-positive breast cancer: a comprehensive review
H Zhong, Z Zhou, H Wang, R Wang, K Shen… - International Journal of …, 2024 - mdpi.com
Epidermal growth factor receptor 2-positive breast cancer (HER2+ BC) is a highly invasive
and malignant type of tumor. Due to its resistance to HER2-targeted therapy, HER2+ BC has …
and malignant type of tumor. Due to its resistance to HER2-targeted therapy, HER2+ BC has …
Recombinant retroviral vectors that express EGF, TGF alpha, NRG2 beta, and the NRG2 beta Q43L mutant
E Wilson, M Scott, V Dwivedi, DJ Riese II, M Zelan - 2024 - protocols.io
Here we describe the construction of recombinant retroviral expression vectors based on
pLXSN-HygR that drive the ectopic expression of the Epidermal Growth Factor (EGF) …
pLXSN-HygR that drive the ectopic expression of the Epidermal Growth Factor (EGF) …